Company Valuation: Cardiol Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 142 43.96 71.77 151 130.4 177.5 - -
Change - -69.05% 63.28% 110.34% -13.65% 36.17% - -
Enterprise Value (EV) 1 142 43.96 36.84 120.4 108.9 162.5 167.3 177.5
Change - -69.05% -16.19% 226.78% -9.5% 49.17% 2.92% 6.13%
P/E -3.19x -1.41x -2.5x -3.63x -3.36x -4.28x -6.62x 42x
PBR - - 2.55x 6.18x 6.41x 8.75x 16x -
PEG - 0x 0.2x -0.2x 0.1x 0.56x 0.2x -0x
Capitalization / Revenue 1,803x - - - - - 53.5x 4.89x
EV / Revenue 1,803x - - - - - 50.4x 4.89x
EV / EBITDA -4.74x -1.07x -1.25x -3x -3.18x -6.9x -10.5x -8.61x
EV / EBIT -3.67x -1.06x -1.24x -2.99x -3.17x -4.63x -6.23x 36.8x
EV / FCF -6.03x - -1.46x -4.8x -4.56x -8x -35.7x -
FCF Yield -16.6% - -68.5% -20.8% -21.9% -12.5% -2.8% -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.73 -0.49 -0.44 -0.51 -0.39 -0.36 -0.2325 0.0367
Distribution rate - - - - - - - -
Net sales 1 0.0788 - - - - - 3.321 36.32
EBITDA 1 -29.95 -41.12 -29.54 -40.11 -34.21 -23.54 -15.88 -20.62
EBIT 1 -38.66 -41.34 -29.79 -40.28 -34.32 -35.09 -26.87 4.821
Net income 1 -31.64 -30.93 -28.13 -36.68 -33.82 -35.21 -30.57 -8.68
Net Debt 1 - - -34.93 -30.58 -21.42 -15.01 -10.26 -
Reference price 2 2.330 0.690 1.100 1.850 1.310 1.540 1.540 1.540
Nbr of stocks (in thousands) 60,954 63,703 65,247 81,603 99,514 115,272 - -
Announcement Date 3/23/22 3/28/23 4/1/24 3/31/25 3/31/26 - - -
1CAD in Million2CAD
Estimates

P/E, Detailed evolution

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
-4.14x - -6.66x - 121M
33.98x5.95x18.43x0.97% 48.62B
-23.46x347.73x-22.18x-.--% 39.86B
24.73x2.75x11.9x-.--% 33.91B
43.93x4.37x27.91x-.--% 32.32B
29.38x7.6x19.54x0.43% 24.73B
31.89x5.17x23.57x-.--% 15.52B
23.77x2.03x8.91x1.13% 13.63B
24.78x1.96x11.87x-.--% 13.41B
Average 20.54x 47.20x 10.37x 0.32% 24.68B
Weighted average by Cap. 21.85x 66.25x 11.01x 0.33%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Valuation Cardiol Therapeutics Inc.